ASCO 2019 | Atezolizumab for TNBC

Erika Hamilton

Erika Hamilton, MD, of the Sarah Cannon Research Institute, Nashville. TN, discusses the use of
atezolizumab for the treatment of triple-negative breast cancer (TNBC). This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics
Related videos
1:26
Comparison of investigator-initiated and industry-initiated trials by Dr Sridhar
Srikala Sridhar
2:46
Radiology advancements and the management of genitourinary cancers
Julia Fielding
1:33
Radiomics updates: data science in radiology
Julia Fielding
1:47
TNBC: work to be done
Peter Schmid
2:30
IMpassion130: immunotherapy for TNBC
Peter Schmid
Breast Cancer, General
Atezolizumab
ASCO 2019
Interview
2nd June 2019
More from Erika Hamilton
Social media: research opportunities
AZD2014 for treating ER+ metastatic breast cancer – mode of action and trial results
ONT-380 for HER2+ metastatic breast cancer: promising results for patients with brain metastases
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals